C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Takes Position in Exact Sciences Co. (NASDAQ:EXAS)

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in Exact Sciences Co. (NASDAQ:EXAS - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 8,508 shares of the medical research company's stock, valued at approximately $478,000.

Several other institutional investors and hedge funds have also bought and sold shares of EXAS. Huntington National Bank boosted its position in Exact Sciences by 838.1% during the third quarter. Huntington National Bank now owns 394 shares of the medical research company's stock valued at $27,000 after purchasing an additional 352 shares during the last quarter. RPg Family Wealth Advisory LLC acquired a new position in Exact Sciences during the third quarter valued at approximately $34,000. Capital Performance Advisors LLP acquired a new position in Exact Sciences during the third quarter valued at approximately $35,000. Vestor Capital LLC acquired a new position in Exact Sciences during the third quarter valued at approximately $46,000. Finally, Asset Planning Inc acquired a new position in Exact Sciences during the fourth quarter valued at approximately $40,000. Institutional investors own 88.82% of the company's stock.

Exact Sciences Price Performance

Exact Sciences stock traded down $0.55 during mid-day trading on Friday, reaching $48.96. 1,647,369 shares of the company were exchanged, compared to its average volume of 2,286,903. The company has a fifty day simple moving average of $55.15 and a 200-day simple moving average of $60.03. Exact Sciences Co. has a 12 month low of $40.62 and a 12 month high of $79.62. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.12 and a quick ratio of 1.93. The firm has a market cap of $9.06 billion, a PE ratio of -8.81 and a beta of 1.24.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 4.97% and a negative net margin of 37.29%. The firm had revenue of $713.42 million for the quarter, compared to analyst estimates of $701.45 million. As a group, equities research analysts expect that Exact Sciences Co. will post -0.59 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on EXAS shares. BTIG Research raised their price objective on Exact Sciences from $65.00 to $75.00 and gave the company a "buy" rating in a research report on Tuesday, November 26th. Jefferies Financial Group raised their price objective on Exact Sciences from $84.00 to $85.00 and gave the company a "buy" rating in a research report on Wednesday, November 6th. Citigroup cut their price objective on Exact Sciences from $80.00 to $75.00 and set a "buy" rating for the company in a research report on Wednesday, November 6th. Piper Sandler cut their price objective on Exact Sciences from $85.00 to $75.00 and set an "overweight" rating for the company in a research report on Monday, November 11th. Finally, Canaccord Genuity Group cut their price objective on Exact Sciences from $95.00 to $75.00 and set a "buy" rating for the company in a research report on Wednesday, November 6th. One analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $72.06.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.